Latest news on Bimekizumab

The U.S. Food and Drug Administration (FDA) has approved Bimekizumab for the treatment of moderate to severe plaque psoriasis in adults receiving systemic therapy or phototherapy. Bimezumab is the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines that drive the inflammatory process - interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

The effects of psoriasis go far beyond the skin itself. In addition to the recognized skin symptoms of itching and peeling, psoriasis can cause stress for patients and their families, affecting work, relationships and home life. A US observational study (n=846) reported that only a quarter of patients achieved self-assessed complete skin clearance after 6 months of treatment with biologics, highlighting the burden of plaque psoriasis and the need for additional new treatment options. In a Phase 3/3b trial, bimezumab achieved higher levels of skin clearance at week 16 compared with placebo and three existing biologics for psoriasis, with responses that were rapid and sustained for up to one year. Long-term data also show that most patients maintain high levels of clinical response over three years.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.